Citius Pharmaceuticals : CTXR Corporate Presentation

Citius Pharmaceuticals, Inc.

(NASDAQ: CTXR)

CORPORATE OVERVIEW MAY 2024

FORWARD-LOOKING STATEMENTS

This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. The information contained in this presentation and the comments and remarks of the representatives of the Company made during any presentation to which this presentation relates are integrally related and, as such, are intended to be delivered and understood together. Information provided in this presentation speaks only as of the date hereof. The Company assumes no obligation to update any statement after the date of this presentation as a result of new information, subsequent events or any other circumstances.

This presentation also includes express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of the Company that are not historical facts. Such forward-looking statements may be identified by words such as "believes", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. The accuracy of such statements is dependent upon future events, and involves known and unknown risks, uncertainties and other factors beyond the Company's control that may cause actual results to differ materially from what is presented herein. Investors are strongly encouraged to carefully review the Company's SEC filings for a listing of the risks that could cause actual results to differ from these forward-looking statements. These forward-looking statements speak only as of the date of this presentation and should not be construed as statements of facts.

NASDAQ: CTXR	2

INVESTMENT HIGHLIGHTS

1 Diversified Pipeline: Building a Biotech Platform

• LYMPHIR : purified reformulation of IL-2 diphtheria toxin fusion protein for CTCL1 (P3 completed)

• Mino-Lok®: potential to be first and onlyFDA-approved product to salvage infected CVCs causing CLABSI (P3 completed)
• Halo-Lido:potential to be first and onlyFDA-approved Rx therapy for hemorrhoids (P2b completed)

1. Attractive Multi-billion $ Global Market Opportunities
2. • CTCL market est. $300-$400+M with larger potential in PTCL and immuno-oncology (I/O)
   • CRBSI/CLABSI market est. >$1.8B worldwide
   • Rx hemorrhoid market est. >$2B US
3. Healthy Financial Platform
4. • $12.6M cash as of 3/31/24
   • $15 M registered direct offering April 2024
   • $26.5 million invested by insiders
5. Anticipated Value Driving Catalysts
6. • Mino-LokPhase 3 trial topline results expected 2Q 2024
   • LYMPHIR BLA PDUFA August 13, 2024; 2H 2024 commercialization expected if approved

1. LYMPHIRTM has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed brand name for I/ONTAK (E7777).

NASDAQ: CTXR

3

MANAGEMENT TEAM WITH PROVEN TRACK RECORD

LEONARD MAZUR

CHAIRMAN

CEO & CO-FOUNDER

GARY TALARICO

EVP, OPERATIONS

JAY WADEKAR

SVP, BUSINESS STRATEGY

MYRON HOLUBIAK

VICE CHAIRMAN & CO-FOUNDER

KELLY CREIGHTON

EVP, CMC

DR. ALAN LADER

SVP, CLINICAL OPERATIONS

JAIME BARTUSHAK	DR. MYRON CZUCZMAN
EVP, CFO & CBO	EVP, CHIEF MEDICAL
	OFFICER

CATHERINE KESSLER	NIK BURLEW
EVP, REGULATORY AFFAIRS	EVP, QUALITY ASSURANCE

MIKE MCGUIRE	ILANIT ALLEN
VP, COMMERCIAL	VP, INVESTOR RELATIONS

NASDAQ: CTXR	4

MINO-LOK

Phase 3 Completed

NASDAQ: CTXR	5

MINO-LOK OVERVIEW

Phase 3 Trial topline data anticipated in 2Q 2024

• First and Only antibiotic lock solution in development to sterilize and salvage infected Central Venous Catheters (CVCs) in patients with catheter-related bloodstream infections
• Mino-Lokaddresses the complications, discomfort and cost of CVC removal and replacement
• Positive Phase 2 data indicated strong safety and efficacy signal
• Phase 3 Trial completed: multi-center, randomized, open label, blinded assessor, active control superiority study
• • Enrollment completed December 2023; data analysis underway
  • 241 patients enrolled; 109 catheter failure events observed
  • Clinical sites in US and India
  • Primary Endpoint: Comparison of Time to Catheter Failure Event

NASDAQ: CTXR	6

MARKET POTENTIAL

High incidence of catheter-related infections support need for effective treatment options

7 Million

Central Venus Catheters (CVCs) used annually in the U.S.*

4 Million

Long-term CVCs

(>1 month) in the U.S.

~500,000

CRBSI/CLABSI infections annually in the U.S.**

12-25%

CRBSI/CLABSI associated mortality & morbidity**

• Shah H., Bosch W., Hellinger W. C., Thompson K. M. (2013). Intravascular catheter-related bloodstream infection. Neurohospitalist 3, 144-151. doi: 10.1177/1941874413476043.
• Antoňáková Němčíková A, Bednárovská E. Catheter-related bloodstream infections: do we know all of it? Klin Onkol. 2017;30(6):405-411. doi: 10.14735/amko2017405.

NASDAQ: CTXR	7

CURRENT STANDARD OF CARE IS A POOR OPTION

SOC catheter removal and replacement presents multiple challenges to patients and

caregivers

• Limited availability of other vascular sites
• Infusion therapy interrupted
• Potential for complications
• • infectious, thrombotic and mechanical
• 57%-67%of patients experience adverse physical and psychological symptoms from catheter R&R*
• High cost
• • ~$10K cost of R&R procedure
  • $46K-$65Kcost of CRBSI/CLABSI episode

• Chaftari, AM et al,. Unnecessary Removal of CVCs in Cancer Patients with CRBSI: Impact on Symptom Burden. Poster presentation at ID Week 2017, Infectious Diseases Society of America (IDSA)Oct 04 - 08, 2017

NASDAQ: CTXR	8

POTENTIAL GOLD STANDARD IN CLABSI TREATMENT

Mino-Lok addresses the complications, discomfort and cost of CVC removal and

replacement

• Limited duration IV therapy

5-7DAYS

• Limits disruption of infusion therapy
• Ease of Administration: Locking a catheter is a well-known standard operating procedure
• Not flushed into the venous system
• Lowers risks to patient
• Lower cost alternative: significantly less than removal and replacement

NASDAQ: CTXR	9

MINO-LOK PHASE 2B TRIAL RESULTS

Mino-Lok® demonstrated a strong safety and efficacy signal

100%	Effective in salvaging CVCs in all
	patients treated with Mino-Lok
100%	Patients treated with Mino-Lok
	all had complete microbiologic
	eradication with no relapse
0%	No SAEs in patients treated with
	Mino-Lok®
0%	Complication rate for Mino-Lok
	patients was 0% vs. 18% for

control arm patients

Mino-Lok Arm	Control Arm
Parameter		%	N	%
N
P atients	30	100%	60	100%
Cancer Type
- Hematologic	20	67%	48	80%
- S olid tumor	10	33%	12	20%
ICU Admission	4	13%	4	7%
Mech. Ventilator	3	10%	-	0%
Bacteremia
- Gram+	17	57%*	32	53%
- Gram -	14	47%*	28	47%
Neutropenia (<500 )	19	63%	36	60%
Microbiologic E radication	30	100%	60	100%
- Relapse	-	0%	3	5%***
Complications	-	0%	8	13%
S AE s related to R&R	-	0%	6	10%
Overall Complication Rate	-	0%	11**	18%

*1 polymicrobial patient had Gr+ and Gr - organism cultured; ** 6 patients had >1

complication; ***all 3 CVCs were removed within 1 month.

NASDAQ: CTXR	10